The effect of drug Lignocaine injection to reduce pain associated during uterus removal surgery: Randomized Controlled Trial
Phase 2
Not yet recruiting
- Conditions
- Health Condition 1: N858- Other specified noninflammatory disorders of uterus
- Registration Number
- CTRI/2024/07/070068
- Lead Sponsor
- All India Institute of Medical Sciences Patna
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Posted for total laparoscopic hysterectomy under general anesthesia
American Society of anaesthesiology-physical status (ASA-PS) I and II.
Exclusion Criteria
1. Allergy to local anaesthetics
2. BMI less than 18.5 kg/m2 and more than 30 kg/m2
3. Hepatic impairment
4. Renal impairment
5. any cardio-pulmonary diseases ( valvular heart disease, conduction block, myocardial depression, heart failure, etc )
6. Seizure and neurological disorder
7. Breastfeeding female
8. Psychiatric disorder
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess and compare perioperative pain outcome by administration of intraoperative intravenous lignocaine and placebo in patients undergoing total laparoscopic hysterectomy by perioperative opioid consumption till 24 hours postoperatively.Timepoint: till 24 hours postoperatively.
- Secondary Outcome Measures
Name Time Method To assess numerical rating score of painTimepoint: at 30 minutes, 2 hours, 6 hours, 24 hours;To assess plasma concentration of IL-6 before surgery and at 24 hours after surgeryTimepoint: before surgery and 24 hours after surgery;To assess the quality of recovery at 24 hours after surgeryTimepoint: at 24 hours;To know the incidence of postoperative nausea and vomitingTimepoint: at 24 hours